How much influence should patients have in drug approval recommendations?
This article was originally published in Scrip
Executive Summary
Just how far should patients be involved in decision-making processes regarding new drug evaluations? It's a question that the European Medicines Agency is poring over as it looks at how best to match regulatory science to clinical needs, based partly on the views of those who are on the receiving end of innovation in medicine.
You may also be interested in...
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.
UK Explains New Rules On Parallel Imports From EU
Guidance from the Medicines and Healthcare products Regulatory Agency says that the packaging of parallel imported medicines must make clear that they are for the UK market only.